Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 5403 Betsy Ross Dr SANTA CLARA CA 95054 |
Tel: | N/A |
Website: | https://shockwavemedical.com |
IR: | See website |
Key People | ||
Douglas Evan Godshall President, Chief Executive Officer, Director | Isaac Zacharias President, Chief Commercial Officer | Renee M. Gaeta Chief Financial Officer |
Business Overview |
Shockwave Medical, Inc. is a medical device company. The Company is primarily engaged in the development and commercialization of novel technologies that transform the care of patients with cardiovascular disease. The Company is focused on its intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular and heart valve disease. Built on a balloon catheter platform, the IVL technology uses lithotripsy to disrupt both superficial and deep vascular calcium., while minimizing soft tissue injury, and an integrated angioplasty balloon to dilate blockages at low pressures, restoring blood flow. Its Shockwave M5 IVL catheter and Shockwave M5+ IVL catheter are five-emitter catheters for use in its IVL System in medium-diameter vessels for the treatment of peripheral artery disease (PAD). Its Shockwave S4 IVL catheter is a four-emitter catheter for use in its IVL System in small-diameter vessels for the treatment of PAD. |
Financial Overview |
For the fiscal year ended 31 December 2023, Shockwave Medical Inc revenues increased 49% to $730.2M. Net income decreased 32% to $147.3M. Revenues reflect Coronary segment increase of 49% to $528.8M, Peripheral segment increase of 47% to $194.3M, United States segment increase of 43% to $581.5M, All Other Countries segment increase from $31.3M to $71.2M. |
Employees: | 1,468 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $12,025M as of Dec 31, 2023 |
Annual revenue (TTM): | $730.23M as of Dec 31, 2023 |
EBITDA (TTM): | $169.45M as of Dec 31, 2023 |
Net annual income (TTM): | $147.28M as of Dec 31, 2023 |
Free cash flow (TTM): | $165.46M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 37,396,816 as of Feb 21, 2024 |
Index Membership: | S&P 400 Mid Cap |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |